TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03111836

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: Received general information about blood pressure control. All subjects will be sent 16 e-messages on a weekly schedule.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Expert-Driven Group
Description: The user-driven e-Counselling group will receive a lifestyle program where the user are able to choose areas of focus. All subjects will be sent 16 e-messages on a weekly schedule.
Study: NCT03955523

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single exercise bout trial
Description: Exercise trial day: 30 min of continuous exercise at 60% VOpeak (or at the least 3 bouts of 10 min at 60% VO2peak separated by no more than 1 minute rest) - power output is set at that determined during the maximum test on the first visit, and adjusted accordingly if there is a deviation \>5% VO2peak for at least 3 minutes of exercise.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Single diet trial
Description: Diet trial day The protocol of the diet trial day is identical to that of the exercise trial day, except that exercise is substituted by asking the participant to eat a standardized breakfast meal that it is commonly consumed in a fast-food chain (i.e. cheese and egg McMuffin, double portion of hash browns and an orange pop).
Study: NCT03664934

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: Neck-specific exercises for chronic whiplash associated disorders
Study: NCT00688870

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (13vPnC)
Description: 13vPnC is given via intramuscular injection at approximately 2, 4, 6, and 15 months of age.
Study: NCT03111836

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: User-driven group
Description: The user-driven e-Counselling group will receive a lifestyle program where the user are able to choose areas of focus. All subjects will be sent 16 e-messages on a weekly schedule.
Study: NCT00688870

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 7-valent pneumococcal conjugate vaccine (7vPnC)
Description: 7vPnC is given via intramuscular injection at approximately 2, 4, 6, and 15 months of age.
Study: NCT02878005

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intubating Laryngeal Tube Suction
Description: Intubating Laryngeal Tube Suction

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intubating Laryngeal Tube Suction
Description: Intubating Laryngeal Tube Suction
Study: NCT02180581

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic (2 * 10^9 cfu/day)
Description: Combination of two probiotics (2 \* 10\^9 cfu/day) or probiotics for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 6 months
Study: NCT01425034

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: casts for the thumb
Description: The 'Cast' group will be placed in a thumb spica short arm cast with the thumb IP joint free. They will be allowed digit, thumb IP and elbow range of motion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motion group
Description: The 'Motion' group will be placed in a forearm based thumb spica splint with the thumb IP free. They will be allowed digit, thumb IP and elbow range of motion.
Study: NCT01402401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUY922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Study: NCT01931423

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placental cord drainage
Study: NCT01548027

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local infiltration group
Description: patients would have 0.5 ml/kg of 0.25% bupivacaine if age \< 6 months or 1 ml/kg if age \> 6 months around the wound by surgeon. The needle will be injected in subcutaneous tissue parallel to the wound.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP block
Description: Surgical TAP block (sTAP: Patients would have 0.5 ml/kg of 0.25% bupivacaine if age \< 6 months or 1 ml/kg if age \> 6 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention
Description: No intervention
Study: NCT03997461

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BPro
Description: BPro and Oscar 2 comparison for 24 hours
Study: NCT04394923

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modification of the pulmonary vein ablation line
Description: The ablation line previously drawn will be modified regarding the esophageal print position in order to avoid RF application within the red layer of the esophageal print.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Regular PVI ablation
Description: Blinded to the esophageal position based on the type of AF, closer to the ostium for paroxysmal AF and wider for persistent AF
Study: NCT00988598

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-04447943
Description: 25 mg of PF-04447943 orally every 12 hours for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 25 mg matching placebo to PF-04447943 orally every 12 hours for 7 days
Study: NCT02347397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SS Bipolar Head + SL-TWIN Stem
Description: Subject will undergo hemiarthroplasty surgery with SS Bipolar Head \& SL-TWIN Stem

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar Head + SL-PLUS Stem
Description: Subject will undergo hemiarthroplasty surgery with Bipolar Head \& SL-PLUS Stem
Study: NCT02579668

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Language Therapy
Study: NCT03881111

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to pembrolizumab (saline) administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle. Duration of cisplatin treatment will be capped at 6 doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: 80 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle. Duration of cisplatin treatment will be capped at 6 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 800 mg/m\^2/day (4000 mg/m\^2 total per cycle) administered as continuous IV infusion on Days 1 to 5 (120 hours) of each 3-week cycle, or per local standard for 5-FU administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-FU
Description: 800 mg/m\^2/day (4000 mg/m\^2 total per cycle) administered as continuous IV infusion on Days 1 to 5 (120 hours) of each 3-week cycle, or per local standard for 5-FU administration.
Study: NCT01212562

Intervention type: PROCEDURE
Intervention: Immunocryosurgery
Description: Assessing the efficacy of cryosurgery during continued imiquimod application (immunocrysurgery) in the treatment of basal cell carcinoma of the skin
Study: NCT01250366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INX-08189
Description: Capsules, Oral, 9 mg, Once Daily, 7 Days
Study: NCT02878005

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambu AuraGain Laryngeal Mask
Description: Ambu AuraGain Laryngeal Mask

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambu AuraGain Laryngeal Mask
Description: Ambu AuraGain Laryngeal Mask
Study: NCT01250366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INX-08189
Description: Capsule, Oral, 25 mg, Once Daily, 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INX-08189
Description: Capsule, Oral, 25 mg, Once Daily, 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INX-08189
Description: Capsules, Oral, 50 mg, Single Dose, 1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INX-08189
Description: Capsules, Oral, 9 mg, Once daily, 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INX-08189
Description: Capsules, Oral, 50 mg, Once daily, 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INX-08189
Description: Capsules, Oral, 9 mg, Once daily, 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INX-08189
Description: Capsules, Oral, 100 mg, Once daily, 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with INX-08189
Description: Capsules, Oral, 0 mg, Once daily, 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with INX-08189
Description: Capsules, Oral, 0 mg, Once daily, 7 days
Study: NCT04323176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Village Model implementation
Description: Participate in the Village Model using a website
Study: NCT03924440

Intervention type: DIAGNOSTIC_TEST
Intervention: Proov (Ovulation Double Check) Test
Description: Rapid response urine progesterone test strips, Proov (formerly named Ovulation Double Check
Study: NCT03014076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP2 peptide + GM-CSF vaccine plus trastuzumab
Description: HLA-A2+/A3+ subjects are given the GP2 peptide vaccine plus trastuzumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: HLA-A2-/A3- patients are followed as controls receiving trastuzumab only.
Study: NCT02094287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimetindene
Description: receiving either dimetindene or a placebo (saline) via infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimetindene
Description: receiving either dimetindene or a placebo (saline) via infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimetindene
Description: receiving either dimetindene or a placebo (saline) via infusion

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: instruction
Description: information about the drug dimetindene and its efficacy versus no information and unawareness of treatment influencing expectations of an efficient treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: instruction
Description: information about the drug dimetindene and its efficacy versus no information and unawareness of treatment influencing expectations of an efficient treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: instruction
Description: information about the drug dimetindene and its efficacy versus no information and unawareness of treatment influencing expectations of an efficient treatment
Study: NCT01250366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with INX-08189
Description: Capsules, Oral, 0 mg, Once daily, 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with INX-08189
Description: Capsules, Oral, 0 mg, Once daily, 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with INX-08189
Description: Capsules, Oral, 0 mg, Once daily, 7 days
Study: NCT02094287

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conditioning
Description: classical conditioning; experiencing and observing the efficiency of a drug manipulated by a conditioning process versus no learning experience.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conditioning
Description: classical conditioning; experiencing and observing the efficiency of a drug manipulated by a conditioning process versus no learning experience.
Study: NCT04078243

Intervention type: DEVICE
Intervention: CardioMEMS HF System
Description: The CardioMEMS HF System is the first and only FDA-approved wireless heart failure monitor. The system is a safe, reliable way to help your patients manage their heart failure.
Study: NCT02920437

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Four-week weekly intervention to reduce salt intake
Description: The intervention group will receive a four-week weekly intervention, about 15 minutes each. Two sessions will be face-to-face and two sessions will be on the phone. The participants will be informed of their 24-hour urinary sodium excretion at each measurement time once available.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual government pamphlets
Description: The control group will receive usual government pamphlets when they know their 24-hour urinary sodium excretion at baseline. However, they will not be informed of their follow-up urinary sodium excretion results immediately.
Study: NCT02103244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin will be dosed according to newly developed dosing algorithm.
Study: NCT00700492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: progesterone
Description: vaginal capsules 3X200mg daily
Study: NCT04831541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11
Description: Each subject receive a single intravenous injection of 68Ga-PSMA-11, and undergo PET/CT imaging within the specificed time.
Study: NCT03259373

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Patient-Level and Provider-Level Educational Intervention
Description: Letters to patients that (1) explain to the patient that he or she appears to have AF, characterize the risk of stroke, and emphasize that although there may be a medical reason, the patient does not seem to be on an anticoagulant and (2) encourage the patient to discuss this with his or her provider to ask if he or she might benefit from OAC therapy to prevent stroke.~Early intervention letters to providers explain this project, the nature of the problem, and identify a list of the provider's patients who have been contacted, as the provider and patient letters will be sent at approximately the same time; describe evidence and guidelines regarding oral anticoagulation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed Provider-Level Educational Intervention
Description: Delayed intervention letters to patients' providers, where they may be identified, that explain this project, the nature of the problem, and identify a list of their patients who are flagged as at risk for stroke and have not been treated with an oral anticoagulant; describe evidence and guidelines regarding oral anticoagulation.
Study: NCT04294927

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Risk-reducing salpingectomy with delayed oophorectomy
Description: * BRCA1: RRS at age 25-40 and RRO at a maximum age of 45 (advised between 35 and 45).~* BRCA2: RRS at age 25-45 and RRO at a maximum age of 50 (advised between age 40 and 50).~* BRIP1, RAD51C, RAD51D: RRS at age 25-50 and RRO at a maximum age of 55 (advised between 45 and 55)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Risk-reducing salpingo-oophorectomy
Description: * BRCA1 at a maximum age of 40 (advised between age 35 and 40)~* BRCA2 at a maximum age of 45 (advised between age 40 and 45)~* BRIP1, RAD51C, RAD51D: at a maximum age of 50 (advised between 45 and 50)
Study: NCT01250366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with INX-08189
Description: Capsules, Oral, 0 mg, Once daily, 7 days
Study: NCT02008851

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neo-kidney augment
Description: Injection of 3.0 x 10e6 selected renal cells into the left kidney of the patient
Study: NCT02832401

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03950050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambroxol
Description: Ambroxol Hydrochloride therapy will be dosed up to 600 mg/day divided to twice a day starting 150 mg for the first month, 300 mg for the following month and 600 mg for the following month.~The study was conducted in accordance with the provisions of the Declaration of Helsinki, Good Clinical Practice guidelines, and local laws and regulations.
Study: NCT02086604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study: NCT01857128

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drawtex dressing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Negative Pressure Wound Therapy
Study: NCT01769651

Intervention type: OTHER
Intervention: methadone replacement therapy
Description: Patients are prescribed Methadone as part of their treatment plan, having been assessed as having opioid dependence syndrome and requiring pharmacological substitution therapy. A bio-psychosocial approach is taken in the treatment management of individuals.
Study: NCT01917539

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment
Description: Sham light treatment will consist of applying the usual eye shields used for PLT, applying the usual skin gel to the facial region, and applying the cooling probe without application of pulsed light therapy treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Light Therapy
Description: Light treatment will consist of applying eye shields used for PLT, applying the skin gel to the facial region, and applying the probe with application of pulsed light therapy treatment.
Study: NCT00888628

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Purified Pancreatic Islets
Description: Islet after kidney transplant in patients with type I diabetes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Given as induction for islet cell transplant
Study: NCT02338973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon gamma-1b
Study: NCT02442336

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Journey AHead
Description: The intervention program will contain information and interactive activities around swallowing concerns, proper oral care, healthy eating and nutrition, speech issues, stress and coping with cancer, and pain management.
Study: NCT02099045

Intervention type: DEVICE
Intervention: Point of Care Ultrasonography
Study: NCT00844532

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Absolute Pro™ Peripheral Self-Expanding Stent System
Description: Absolute Pro™ Peripheral Self-Expanding Stent System: Devices include both Absolute Pro™ and Absolute Pro™ LL Peripheral Self-Expanding Stent Systems. It is indicated for the treatment of a maximum of two bilateral de novo or restenotic atherosclerotic lesions in the native common iliac artery and/or native external iliac artery (one lesion per side).
Study: NCT03374527

Intervention type: OTHER
Intervention: blood sample collection
Description: Blood samples are collected from patients with psoriasis vulgaris and patients with psoriatic arthritis following the routine procedure. Blood samples will also be collected from healthy control subjects.

Intervention type: OTHER
Intervention: blood sample collection
Description: Blood samples are collected from patients with psoriasis vulgaris and patients with psoriatic arthritis following the routine procedure. Blood samples will also be collected from healthy control subjects.

Intervention type: OTHER
Intervention: blood sample collection
Description: Blood samples are collected from patients with psoriasis vulgaris and patients with psoriatic arthritis following the routine procedure. Blood samples will also be collected from healthy control subjects.

Intervention type: PROCEDURE
Intervention: Synovial Fluid collection
Description: Synovial fluid is collected when prescribed in patients with psoriatic arthritis
Study: NCT02505438

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Study: NCT00749034

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VPM1002
Description: live vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG
Description: commercially available live vaccine BCG
Study: NCT04621513

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser acupuncture (RJ laser S/N 1813458)
Description: use a low-level-laser acupuncture on acupoint

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: western medicine
Description: Montelukast 4mg 1 tablet HS AVAMYS nasal spray 27.5μg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: western medicine
Description: Montelukast 4mg 1 tablet HS AVAMYS nasal spray 27.5μg QD
Study: NCT01124331

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Higher oxygen saturation target range (91%-95%)
Description: higher (SpO2 91-95%) functional oxygen saturation target range from birth, or soon thereafter

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lower oxygen saturation (85%-89%)
Description: Lower (SpO2 85%-89%)functional oxygen saturation target range from birth, or soon thereafter
Study: NCT00351663

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparine
Description: Patients considered eligible will be divided into 2 groups- those receiving vasopressor support and those not receiving vasopressor support at the time of inclusion. The patients in each group will be randomized to receive enoxaparin in accordance with one of the following DVT prophylaxis protocols:~1. Intravenous Enoxaparine according to their weight (0.5mg/kg x 1/day)~2. Subcutaneous Enoxaparine according to their weight (0.5mg/kg x 1/day)~3. Subcutaneous Enoxaparine 40mg x1/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparine
Description: Patients considered eligible will be divided into 2 groups- those receiving vasopressor support and those not receiving vasopressor support at the time of inclusion. The patients in each group will be randomized to receive enoxaparin in accordance with one of the following DVT prophylaxis protocols:~1. Intravenous Enoxaparine according to their weight (0.5mg/kg x 1/day)~2. Subcutaneous Enoxaparine according to their weight (0.5mg/kg x 1/day)~3. Subcutaneous Enoxaparine 40mg x1/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparine
Description: Patients considered eligible will be divided into 2 groups- those receiving vasopressor support and those not receiving vasopressor support at the time of inclusion. The patients in each group will be randomized to receive enoxaparin in accordance with one of the following DVT prophylaxis protocols:~1. Intravenous Enoxaparine according to their weight (0.5mg/kg x 1/day)~2. Subcutaneous Enoxaparine according to their weight (0.5mg/kg x 1/day)~3. Subcutaneous Enoxaparine 40mg x1/day